Lynparza

Description

Lynparza (Olaparib 100 mg/150 mg) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for:

Ovarian Cancer Treatment:

Maintenance Treatment for BRCA-mutated Cancer: This treatment is for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer with confirmed or suspected BRCA mutations. It is intended for those with a complete or partial response to first-line platinum-based chemotherapy.
Combination Treatment with Bevacizumab: For adults with HRD-positive advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, this treatment combines with bevacizumab for patients responding to first-line platinum-based chemotherapy. A deleterious BRCA mutation or genomic instability defines HRD-positive status.
Treatment for Recurrent BRCA-mutated Cancer: This is aimed at adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with BRCA mutations, who have responded to platinum-based chemotherapy.
Breast Cancer Treatment:

Early Breast Cancer: For adults with HER2-negative, high-risk early breast cancer who have a deleterious or suspected deleterious gBRCA mutation and have received neoadjuvant or adjuvant chemotherapy.
Metastatic Breast Cancer: For adults with HER2-negative metastatic breast cancer who have a deleterious or suspected deleterious gBRCA mutation and have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with HR-positive breast cancer should have previously received endocrine therapy or been deemed unsuitable for it.
Pancreatic Cancer Treatment:

Maintenance treatment for adult patients with harmful or potentially harmful gBRCAm metastatic pancreatic adenocarcinoma, whose disease has remained stable after at least 16 weeks of first-line platinum-based chemotherapy.
Prostate Cancer Treatment:

For adult patients with germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with enzalutamide or abiraterone.
In combination with abiraterone and prednisone or prednisolone for adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
Recommended Dosage: The recommended dosage of Lynparza tablets is 300 mg, taken orally twice a day, with or without food. Patients with metastatic castration-resistant prostate cancer (mCRPC) should also use a gonadotropin-releasing hormone (GnRH) analog concurrently or have undergone a bilateral orchiectomy. For patients with moderate renal impairment (creatinine clearance of 31-50 mL/min), the dosage should be reduced to 200 mg orally twice daily.

If a patient misses a dose of Lynparza, they should take the next dose at the regular scheduled time. Patients should be advised to swallow the tablets whole without chewing, crushing, dissolving, or dividing them.